dc.contributor.author | Morschhauser, F | |
dc.contributor.author | Dyer, MJS | |
dc.contributor.author | Walter, HS | |
dc.contributor.author | Danilov, AV | |
dc.contributor.author | Ysebaert, L | |
dc.contributor.author | Hodson, DJ | |
dc.contributor.author | Fegan, C | |
dc.contributor.author | Rule, Simon | |
dc.contributor.author | Radford, J | |
dc.contributor.author | Cartron, G | |
dc.contributor.author | Bouabdallah, K | |
dc.contributor.author | Davies, AJ | |
dc.contributor.author | Spurgeon, S | |
dc.contributor.author | Rajakumaraswamy, N | |
dc.contributor.author | Li, B | |
dc.contributor.author | Humeniuk, R | |
dc.contributor.author | Huang, X | |
dc.contributor.author | Bhargava, P | |
dc.contributor.author | Jürgensmeier, JM | |
dc.contributor.author | Salles, G | |
dc.date.accessioned | 2021-10-19T08:55:30Z | |
dc.date.issued | 2021-07 | |
dc.identifier.issn | 0887-6924 | |
dc.identifier.issn | 1476-5551 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/18096 | |
dc.format.extent | 2108-2113 | |
dc.format.medium | Print-Electronic | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | Springer Nature [academic journals on nature.com] | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Antineoplastic Agents | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Imidazoles | |
dc.subject | Indazoles | |
dc.subject | Lymphoma, B-Cell | |
dc.subject | Male | |
dc.subject | Middle Aged | |
dc.subject | Protein Kinase Inhibitors | |
dc.subject | Purines | |
dc.subject | Pyrazines | |
dc.subject | Pyrimidines | |
dc.subject | Quinazolinones | |
dc.title | Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma. | |
dc.type | journal-article | |
dc.type | Clinical Trial, Phase I | |
dc.type | Journal Article | |
dc.type | Multicenter Study | |
dc.type | Research Support, Non-U.S. Gov't | |
plymouth.author-url | https://www.ncbi.nlm.nih.gov/pubmed/33328591 | |
plymouth.issue | 7 | |
plymouth.volume | 35 | |
plymouth.publication-status | Published | |
plymouth.journal | Leukemia | |
dc.identifier.doi | 10.1038/s41375-020-01108-x | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/Peninsula Medical School | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CCT&PS | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
dc.publisher.place | England | |
dcterms.dateAccepted | 2020-11-30 | |
dc.rights.embargodate | 2021-10-20 | |
dc.identifier.eissn | 1476-5551 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.versionofrecord | 10.1038/s41375-020-01108-x | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2021-07 | |
rioxxterms.type | Journal Article/Review | |